See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

Injection Site Awareness Week

Dr. Stuart Bootle, MB ChB

Injection Site Awareness Week

Todd speaks about Levemir

Todd Hobbs

Todd speaks about Levemir

The World's First Diabetes Emergency Kit

Gillian Miller - Diabetes and More

The World's First Diabetes Emergency Kit

Diabetes and Byetta

Page 3
Altea Partners With Amylin and Lilly to Develop 12-Hour Byetta Skin Patch
Apr 7, 2009 | 
Buoyed by its recent successful phase 1 human clinical trial of a patch that delivers basal insulin through the skin, Atlanta-based Altea Therapeutics says it will work with Eli Lilly and Company and Amylin Pharmaceuticals, Inc., to develop a daily transdermal patch that deliver sustained levels of Byetta (exenatide). The patch, in a 12- and a 24-hour form, will use the company's proprietary PassPort Transdermal Delivery System. Lilly and Amylin will fund all development, manufacturing, and marketing activities for the product. 
FDA Poised to Review Two New Drugs for Type 2 Diabetes
Mar 24, 2009 | 
The FDA has announced that starting in early April, its Endocrinologic and Metabolic Drugs Advisory Committee will begin looking into two new drugs for type 2 diabetes: saxagliptin tablets from Bristol-Meyers Squibb and liraglutide, an injection drug from Novo Nordisk.
DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

Injection Site Awareness Week

Dr. Stuart Bootle, MB ChB

Injection Site Awareness Week

Todd speaks about Levemir

Todd Hobbs

Todd speaks about Levemir

The World's First Diabetes Emergency Kit

Gillian Miller - Diabetes and More

The World's First Diabetes Emergency Kit

How Diabetes Topics in the News Can Start to Feel Like a Game of “Telephone”
Oct 27, 2008 | 
A recent Wall Street Journal article shows once again how misinformation about diabetes-related topics can be spread by even the most expert journalists.
Amylin’s Woes Mount, Thanks to FDA Actions
Oct 13, 2008 | 
The stock of Byetta manufacturer Amylin Pharmaceuticals has lost more than half of its value over the past eight weeks, thanks to FDA concerns that the type 2 treatment may be connected with the deaths from acute pancreatitis of six Byetta users. Although the FDA has not proven a direct association between fatal pancreatitis and the use of Byetta, Amylin's stock has fallen nevertheless.
Good News for Byetta (Exenatide): Canadian Study Reports Once-Weekly Dose Is Better at BG Control Than Twice Daily
Sep 11, 2008 | 
A Canadian clinical study has delivered a double dose of good news for proponents of exenatide (sold commercially as Byetta), a drug used by more than 700,000 Americans to control blood glucose, ease food cravings, and, incidentally, lose weight.  
Byetta Breaks the Piggy Bank
Jul 31, 2008 | 
San Diego-based Amylin Pharmaceuticals, Inc., posted a second-quarter loss of $64.8 million, or 47 cents per share. This compares to a 2007 second-quarter loss of 45 million, or 34 cents a share.
Can Byetta Be a Standalone Treatment for Type 2?
Apr 2, 2008 | 
Since its introduction in 2005, Byetta has become “the talk of the town” as one of the most powerful, yet benign, diabetes drugs of the 21st century.
Next Page » « Previous Page
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.